Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.48 |
| ▸ | FNTB | P49356 | 4/20 | 0.48 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372490 | 1.00 | FNTA (0.48) | FNTAFNTBPGGT1BLMNAGAA | |
| SCHEMBL7840054 | 0.92 | FNTA (0.49) | FNTAFNTBPGGT1BLMNAGAA | |
| SCHEMBL5371230 | 0.89 | LMNA (0.39) | FNTAFNTBPGGT1BLMNAGAA | |
| SCHEMBL7839572 | 0.87 | FNTA (0.55) | FNTAFNTBPGGT1BLMNAGAA | |
| SCHEMBL446699 | 0.87 | FNTA (0.53) | FNTAFNTBPGGT1BLMNAGAA | |
| SCHEMBL7847643 | 0.86 | FNTA (0.48) | FNTAFNTBPGGT1BLMNAMAPK1 | |
| SCHEMBL7848346 | 0.86 | FNTA (0.49) | FNTAFNTBPGGT1BLMNAGAA | |
| SCHEMBL7839131 | 0.85 | FNTA (0.51) | FNTAFNTBPGGT1BLMNAGAA | |
| SCHEMBL7838097 | 0.84 | FNTA (0.55) | FNTAFNTBPGGT1BLMNAGAA | |
| SCHEMBL7856913 | 0.84 | FNTA (0.61) | FNTAFNTBPGGT1BLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-0944388-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2001-08-16 | — | — | EP | claimed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | claimed |
| EP-0944388-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1997038665-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | claimed |
| CN-108289922-B | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210205389-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | CHANG GUNG MEDICAL FOUND KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-07-08 | — | — | US | disclosed |
| US-10953059-B2 | Methods and compositions for treating non-small cell lung cancer | CHANG GUNG MEDICAL FOUNDATION KEELUNG CHANG GUNG MEMORIAL HOSPITAL (TW) | 2021-03-23 | — | — | US | disclosed |
| EP-3310174-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | OP NANO CO., LTD. (TW) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016197012-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | ORIENT PHARMA INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-9505784-B2 | Fused 2-aminothiazole compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-6313138-B1 | FOR THERAPY OF ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES IN MAMMALS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| US-6306874-B1 | ENZYME INHIBITORS SUCH AS ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES, AND THE LIKE IN MAMMALS. | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0944388-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6248756-B1 | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. | 2001-06-19 | — | — | US | disclosed |
| US-6245759-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
| EP-0944388-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1997038665-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.